^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IBR854

    i
    Other names: IBR854, Anti-5T4 CAR-raNK
    Associations

    News

    Trials
    Company:
    Imbioray Bio
    Drug class:
    5T4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Imbioray (Hangzhou) Biomedicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    IBR854
    2years
    Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=56, Recruiting, Shanghai East Hospital | Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Aug 2022 --> Apr 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1) • IL10 (Interleukin 10)
    |
    EGFR mutation
    |
    IBR854
    over2years
    Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=56, Recruiting, Shanghai East Hospital | N=136 --> 56
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1) • IL10 (Interleukin 10)
    |
    EGFR mutation
    |
    IBR854